Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma

肿瘤相关巨噬细胞在成人经典型霍奇金淋巴瘤中的预后和临床价值的荟萃分析

阅读:1

Abstract

BACKGROUND: The prognostic significance of tumor-associated macrophages (TAM) in adult classical Hodgkin lymphoma (cHL) remains controversial. Here, we report a meta-analysis of the association of CD68 and CD163 infiltration on the clinical outcome of adult cHL. METHODS: A comprehensive search to identify relevant articles was performed in PubMed, Embase, and Google Scholar on January 31, 2016. Using the fixed effect or random effects model of DerSimonian and Laird, hazard ratios (HR) or odds ratios (OR) with 95 % confidence intervals (CIs) were used as the effect size estimate. RESULTS: Twenty-two eligible studies with a total of 2959 patients were identified. Our analysis indicated that a high density of CD68(+) TAMs in the tumor microenvironment of adult cHL predicted poor overall survival (OS) (HR: 2.41; 95 % CI, 1.92-3.03), shorter progression-free survival (PFS) (HR: 1.78; 95 % CI, 1.45-2.18), and poor disease-specific survival (HR: 2.71; 95 % CI, 1.38-5.29). High density of CD163(+) TAMs in the tumor microenvironment of adult cHL also predicted poor OS (HR: 2.75; 95 % CI, 1.58-4.78) and poor PFS (HR: 1.66; 95 % CI, 1.22-2.27). In addition, we demonstrated that a high density of either CD68(+) or CD163(+) TAMs was associated with the presence of Epstein-Barr virus in neoplastic cells (OR(CD68): 3.13; 95 % CI, 2.02-4.84; OR(CD163): 2.88; 95 % CI, 1.55-5.34). A high density of either CD68(+) or CD163(+) TAMs tend to be associated with a more advanced clinical stage (OR(CD68): 1.25; 95 % CI, 0.93-1.67; OR (CD163): 1.19; 95 % CI, 0.86-1.63), B-symptoms (OR(CD68): 1.35; 95 % CI, 0.90-2.01; OR(CD163): 2.19; 95 % CI, 0.96-5.03), higher International Prognostic Factors Project Score (OR(CD68): 1.20; 95 % CI, 0.67-2.15; OR(CD163): 2.00; 95 % CI, 0.92-4.35), and bulky disease (OR(CD68): 1.47; 95 % CI, 0.88-2.47; OR(CD163): 1.19; 95 % CI, 0.72-1.96). CONCLUSIONS: Our analyses suggest that a high density of either CD68(+) or CD163(+) TAMs is a robust predictor of adverse outcomes in adult cHL. Increased TAMs should be taken into account to further improve prognostic stratification and the planning of appropriate therapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。